Skip to main content
Profile picture for Jack Cush, MD

Jack Cush, MD

Dr. Cush is the Executive Editor of RheumNow.com and also Co-Edits the online textbook RheumaKnowledgy.com. 
  
Dr. Cush's interests include medical education, novel drug development, rheumatoid arthritis, spondyloarthritis, drug safety, and Still's disease/autoinflammatory syndromes. He has published over 140 articles and 2 books in rheumatology.
 
He can be followed on twitter: @RheumNow

Articles By Jack Cush, MD

rwcs2016.jpg

RWCS 2016 – Rheumatoid Review, Psoriatic Arthritis and Medical Marijuana

The Rheumatology Winter Clinical Symposia launched its 9th annual conference yesterday in Maui. Highlights of this meeting will be covered by RheumNow from Wednesday 2/10 till Saturday 2/13. Rheumatoid Arthritis Year in Review

Read Article
bone%20dense.jpg (keep)

What To Do After Teriparatide?

Once the clock runs out on teriparatide (TPTD or Forteo), what is the next best option?

Read Article
pilldollars_400_400_90.jpg

Rheumatoid Modern Management is Better but More Costly

The mantra of rheumatologists worldwide is to treat rheumatoid arthritis (RA) earlier and more aggressively. While referral of early RA patients has improved, there is little data demonstrating that more aggressive treatment works or is cost effective.

Read Article
FDA.Biosimilar.png

FDA Advisory Arthritis Committee Votes to Approve the CT-P13 (infliximab) Biosimilar

On Tuesday February 9th Celltrion presented its biosimilar developmental data to the FDA as they sought approval for their CT-P13 (called Inflectra), a biosimilar of infliximab (Remicade).

Read Article
%E2%80%ADbiosim.cartoon.png

FDA Reviews Celltrion's Remicade Biosimilar Today

The arthritis advisory committee of the Food and Drug Administration (FDA) is scheduled to meet today, February 9th to review the efficacy and safety of Celltrion's biosimilar form of infliximab (Remicade) that is currently marketed in other countries.

Read Article
JIA_0.jpg

Parenteral Methotrexate Intolerance is High in Juvenile Idiopathic Arthritis

Juvenile idiopathic arthritis (JIA) is commonly managed with methotrexate (MTX), with many pediatric rheumatologists preferring to use parenteral MTX for compliance and absorption reasons.

Read Article
heart-665185__180.jpg

Racial Disparity in Cardiovascular Risks with Connective Tissue Disorders

Cardiovascular events account for significant morbidity and mortality in patients with rheumatoid arthritis (RA) and other connnective tissue disorders (CTD). Investigators analyzed health records from a large U.S.

Read Article

The Week in Review: 5 February 2016

Dr. Cush reviews highlights from last week's news and research in rheumatology.

Read Article
research2.jpg

Arthritis Foundation Awards $5.5 Million to 11 Investigators

The Arthritis Foundation announced that 11 scientists were selected out of 167 proposals as the 2015 Scientific Discovery Awardees for their innovations toward finding a cure for arthritis and related diseases.

Read Article
Lupusfoto.jpg

Young Lupus Patients Have Higher Mortality Risk

A retrospective study examined mortality rates by comparing 2740 UK lupus patients  who were matched 1:4 with controls from the UK Clinical Practice Research Datalink between 1999 and 2012. (Citation source http://buff.ly/1nJWKIT)

Read Article
×